An interventional study of Placebo and Pregabalin in Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing pregabalin in Pain — 4 open to participants now, 4 under way, none of them phase 3. Pregabalin · Pain.
Among the 55 studies testing pregabalin in Pain, this one is the 48th largest by enrollment, is one of 7 that started in 2008, is one of 14 with no phase, and was the 8th registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →4 of the 55 studies testing pregabalin in Pain are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 17 · Phase 4 14
First in 2001; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 64 across the 55 interventional studies. Of the 47 that completed or were terminated, 18 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
22 studies in Pain by Viatris Inc.: none open now, none under way, none of them phase 3. Of 22 finished, 18 (82%) have results posted.
Among the 22 studies in Pain by Viatris Inc., this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2008, is one of 3 with no phase, and was the 4th registered.
Viatris Inc.’s Pain studies by the year they started, since 2006.
3 of the studies testing pregabalin in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186751Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07208357Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07171320Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 55 studies testing pregabalin in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 22 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a methodology study designed to discover whether a brain imaging technology is a better way of compare the relative sensitivities of fMRI and subjective psychometric assessments of pain to multiple doses of pregabalin and tramadol SR in a cross-over clinical study design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Pregabalin
Drug: Tramadol SR
BID
Dose 75 mg titrated to 150 mg, bid
Dose 50mg titrated to 200 mg, bid
Voxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals Across the Whole Brain
BOLD brain activation signals in whole brain was assessed using Contrast Parameter Estimates (COPE) images in response to dynamic mechanical allodynia of the affected side (DMAa), dynamic mechanical allodynia of the control side (DMAc), thermal pain (TH) and checkerboard visual stimuli (VIS).
Time frame: Day 8, 22, 36
Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Dynamic Mechanical Allodynia of the Affected Side (DMAa)
BOLD brain activation signals in pre-defined region of interest(ROI):anterior cingulate cortex(ACC);left,right anterior cortex(\[AIC_L \],\[AIC_R\]);left,right mid-insular cortex(\[MIC_L\],\[MIC_R\]);left,right posterior insular cortex(\[PIC_L\],\[PIC_R\]);left,right amygdala(\[Amyg_L\],\[Amyg_R\]);primary,secondary somatosensory cortex(\[S1\],\[S2\]);sensory part of thalamus(SensTHAL);midbrain reticular formation(MRF);nucleus cuneiformis(NucCun);periaqueductal gray(PAG). Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis,signal change is unit less measure but approximated to percent signal change by grand scaling(effects divided by 10000 to get percent signal change).
Time frame: Day 8, 22, 36
Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Dynamic Mechanical Allodynia of the Control Side (DMAc)
BOLD brain activation signals in pre-defined ROI. ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis, signal change is unit less measure but is approximated to percent signal change here by grand scaling (dividing effects by 10000 to get percent signal change).
Time frame: Day 8, 22, 36
Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Thermal Stimulation (TH)
BOLD brain activation signals in pre-defined ROI. ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis, signal change is unit less measure but is approximated to percent signal change here by grand scaling (dividing effects by 10000 to get percent signal change).
Time frame: Day 8, 22, 36
Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Visual Stimulation (VIS)
BOLD brain activation signals in pre-defined ROI in response to checkerboard visual stimuli (flashing at 2 Hz). ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only.
Time frame: Day 8, 22, 36
Arterial Spin Labelling (ASL) Using fMRI of Brain Activation Signals Across the Whole Brain and in Defined Brain Regions
Continuous ASL sequence fMRI imaging modality assessing brain activation signals across the whole brain and in defined ROI to assess effects of evoked pain along with changes in regional cerebral blood flow (rCBF). ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG.
Time frame: Day 8, 22, 36
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Time frame: Day 8, 22, 36
Beck Depression Inventory (BDI)
BDI is a 21 item participant rated inventory evaluating depression symptoms, cognition, and physical symptoms of fatigue, weight loss, lack of interest in sex. Individual items are scored on a 4 point scale (0 to 3), with 0=none/absent and 3=most severe. Total score: 0 to 63; higher score indicate more depression.
Time frame: Day 8, 22, 36
State and Trait Anxiety Questionnaire
Self-report scale completed by the participant. Separate scales measure state (20 items) and trait (20 items) anxiety. The participant report how they feel "right now at this moment" for state anxiety and how they "generally" feel for trait anxiety. The "state" items are scored as: 1 (not at all), 2 (somewhat true), 3 (moderately true), 4 (very much so). The "trait" items are scored as: 1 (almost never), 2 (sometimes), 3 (often), 4 (almost always). Scores range from 20-80 for each scale. Higher scores indicate more impaired participants.
Time frame: Day 8, 22, 36
Pain Catastrophising Scale (PCS)
The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all questions (range: 0 to 52); Subscale scores: Rumination (sum of scores for 4 items; range: 0 to 16); Magnification (sum of scores for 3 items; range: 0 to 12); and Helplessness (sum of scores for 6 items; range: 0 to 24); higher scores indicate greater extent of pain catastrophizing.
Time frame: Day 8, 22, 36
Neuropathic Pain Symptom Inventory (NPSI)
NPSI: participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicate a greater intensity of pain.
Time frame: Baseline (Day -7), Day 8, 22, 36
Daily Pain Score
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning using 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). The daily pain scores for an average of the last 7 days and an average of last 3 days were calculated.
Time frame: Day -35 through Day 36
Present Pain Intensity Score (PPIS)
Participants answered: "Please rate your pain from 0-10 that best describes the intensity of pain right now". PPIS assessed on 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).
Time frame: Day 8, 22, 36
Doleur Neuropathic 4 (DN4) Score
DN4 questionnaire provides a simple diagnosis of Neuropathic pain (NeP) by asking for yes/no answers to 4 questions (10 sub questions in total). Each question was scored on a scale of 0 (No) and 1 (Yes). Total score was calculated as sum of the 10 individual questions. Total score range 0-10, higher score indicated more neuropathic pain.
Time frame: Day -35
| Milestone | Pregabalin Then Tramadol Then Placebo | Tramadol Then Placebo Then Pregabalin | Placebo Then Pregabalin Then Tramadol | Pregabalin Then Placebo Then Tramadol | Placebo Then Tramadol Then Pregabalin | Tramadol Then Pregabalin Then Placebo |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 4 | 3 | 3 | 1 |
| Completed | 4 | 3 | 3 | 3 | 3 | 1 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Pregabalin Then Tramadol Then Placebo | Tramadol Then Placebo Then Pregabalin | Placebo Then Pregabalin Then Tramadol | Pregabalin Then Placebo Then Tramadol | Placebo Then Tramadol Then Pregabalin | Tramadol Then Pregabalin Then Placebo |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 3 | 1 |
| Completed | 4 | 3 | 3 | 3 | 3 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Pregabalin Then Tramadol Then Placebo | Tramadol Then Placebo Then Pregabalin | Placebo Then Pregabalin Then Tramadol | Pregabalin Then Placebo Then Tramadol | Placebo Then Tramadol Then Pregabalin | Tramadol Then Pregabalin Then Placebo |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 3 | 1 |
| Completed | 4 | 3 | 3 | 3 | 3 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Pregabalin Then Tramadol Then Placebo | Tramadol Then Placebo Then Pregabalin | Placebo Then Pregabalin Then Tramadol | Pregabalin Then Placebo Then Tramadol | Placebo Then Tramadol Then Pregabalin | Tramadol Then Pregabalin Then Placebo |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 3 | 1 |
| Completed | 4 | 3 | 3 | 3 | 3 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Pregabalin Then Tramadol Then Placebo | Tramadol Then Placebo Then Pregabalin | Placebo Then Pregabalin Then Tramadol | Pregabalin Then Placebo Then Tramadol | Placebo Then Tramadol Then Pregabalin | Tramadol Then Pregabalin Then Placebo |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 3 | 1 |
| Completed | 3 | 3 | 3 | 3 | 3 | 1 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 |
BOLD brain activation signals in whole brain was assessed using Contrast Parameter Estimates (COPE) images in response to dynamic mechanical allodynia of the affected side (DMAa), dynamic mechanical allodynia of the control side (DMAc), thermal pain (TH) and checkerboard visual stimuli (VIS).
No measurements were reported for this outcome.
BOLD brain activation signals in pre-defined region of interest(ROI):anterior cingulate cortex(ACC);left,right anterior cortex(\[AIC_L \],\[AIC_R\]);left,right mid-insular cortex(\[MIC_L\],\[MIC_R\]);left,right posterior insular cortex(\[PIC_L\],\[PIC_R\]);left,right amygdala(\[Amyg_L\],\[Amyg_R\]);primary,secondary somatosensory cortex(\[S1\],\[S2\]);sensory part of thalamus(SensTHAL);midbrain reticular formation(MRF);nucleus cuneiformis(NucCun);periaqueductal gray(PAG). Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis,signal change is unit less measure but approximated to percent signal change by grand scaling(effects divided by 10000 to get percent signal change).
| percent signal change | Pregabalin | Tramadol | Placebo |
|---|---|---|---|
| ACC | -17.3 ± 9.7 | 18.6 ± 9.7 | 7.4 ± 9.7 |
| AIC_L | 8.1 ± 8.8 | 23.3 ± 8.8 | 30.8 ± 8.8 |
| AIC_R | 11.1 ± 10.0 | 21.9 ± 10.0 | 17.1 ± 10.0 |
| MIC_L | 3.8 ± 8.4 | 23.4 ± 8.4 | 30.0 ± 8.4 |
| MIC_R | 8.6 ± 8.4 | 13.4 ± 8.4 | 18.3 ± 8.4 |
| PIC_L | -6.8 ± 5.2 | -5.8 ± 5.2 | -0.3 ± 5.2 |
| PIC_R | -13.6 ± 8.5 | 2.9 ± 8.5 | 6.5 ± 8.5 |
| Amyg_L | -5.7 ± 10.2 | 5.5 ± 10.2 | 8.5 ± 10.2 |
| Amyg_R | -1.4 ± 8.5 | 20.3 ± 8.5 | 21.7 ± 8.5 |
| S1 | -28.5 ± 20.5 | -4.1 ± 20.5 | -2.9 ± 20.5 |
| S2 | 2.5 ± 10.8 | -3.2 ± 10.8 | 10.8 ± 10.8 |
| SensTHAL | 8.0 ± 5.4 | 16.5 ± 5.4 | 9.6 ± 5.4 |
| MRF | 7.0 ± 5.0 | 6.4 ± 5.0 | 11.7 ± 5.0 |
| NucCun | 1.1 ± 5.5 | -0.9 ± 5.5 | 12.9 ± 5.5 |
| PAG | -3.8 ± 7.9 | -15.3 ± 7.9 | 2.5 ± 7.9 |
BOLD brain activation signals in pre-defined ROI. ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis, signal change is unit less measure but is approximated to percent signal change here by grand scaling (dividing effects by 10000 to get percent signal change).
| percent signal change | Pregabalin | Tramadol | Placebo |
|---|---|---|---|
| ACC | -22.3 ± 12.0 | -3.7 ± 12.0 | 0.2 ± 12.0 |
| AIC_L | -13.5 ± 8.0 | 18.2 ± 8.0 | 20.2 ± 8.0 |
| AIC_R | -10.6 ± 7.4 | 10.3 ± 7.4 | 20.2 ± 7.4 |
| MIC_L | -7.6 ± 8.4 | 9.7 ± 8.4 | 9.0 ± 8.4 |
| MIC_R | -9.2 ± 6.2 | 2.8 ± 6.2 | 0.7 ± 6.2 |
| PIC_L | -14.9 ± 6.9 | -8.1 ± 6.9 | 0.8 ± 6.9 |
| PIC_R | -17.2 ± 9.4 | 2.4 ± 9.4 | 6.3 ± 9.4 |
| Amyg_L | -14.3 ± 7.3 | 1.5 ± 7.3 | -3.4 ± 7.3 |
| Amyg_R | -10.3 ± 9.7 | 2.0 ± 9.7 | -3.8 ± 9.7 |
| S1 | -31.6 ± 16.2 | -4.5 ± 16.2 | 14.6 ± 16.2 |
| S2 | -0.4 ± 8.3 | 9.6 ± 8.3 | 13.5 ± 8.3 |
| SensTHAL | 3.9 ± 5.3 | -2.8 ± 5.3 | 6.7 ± 5.3 |
| MRF | 1.5 ± 4.6 | -6.6 ± 4.6 | -1.7 ± 4.6 |
| NucCun | 1.0 ± 4.9 | -8.2 ± 4.9 | -1.8 ± 4.9 |
| PAG | 1.6 ± 7.8 | -12.0 ± 7.8 | -5.0 ± 7.8 |
BOLD brain activation signals in pre-defined ROI. ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis, signal change is unit less measure but is approximated to percent signal change here by grand scaling (dividing effects by 10000 to get percent signal change).
| percent signal change | Pregabalin | Tramadol | Placebo |
|---|---|---|---|
| ACC | 102.2 ± 25.9 | 92.5 ± 25.8 | 83.3 ± 25.8 |
| AIC_L | 92.1 ± 21.9 | 103.4 ± 21.8 | 118.7 ± 21.8 |
| AIC_R | 121.7 ± 20.7 | 104.6 ± 20.6 | 104.0 ± 20.6 |
| MIC_L | 93.4 ± 19.6 | 105.2 ± 19.5 | 100.4 ± 19.5 |
| MIC_R | 106.6 ± 17.3 | 71.1 ± 17.3 | 92.0 ± 17.3 |
| PIC_L | 31.2 ± 16.0 | 44.6 ± 15.9 | 34.2 ± 15.9 |
| PIC_R | 75.3 ± 20.1 | 95.5 ± 20.0 | 91.8 ± 20.0 |
| Amyg_L | 29.7 ± 16.5 | 24.9 ± 16.5 | 36.4 ± 16.5 |
| Amyg_R | 77.5 ± 22.5 | 57.2 ± 22.5 | 67.0 ± 22.5 |
| S1 | -49.0 ± 30.2 | 37.7 ± 30.1 | 27.7 ± 30.1 |
| S2 | 73.6 ± 21.2 | 94.6 ± 21.2 | 74.5 ± 21.2 |
| SensTHAL | 19.4 ± 12.1 | 0.8 ± 12.1 | 10.4 ± 12.1 |
| MRF | 34.3 ± 14.7 | 25.5 ± 14.6 | 37.7 ± 14.6 |
| NucCun | 38.7 ± 11.5 | 27.7 ± 11.5 | 40.5 ± 11.5 |
| PAG | 63.3 ± 15.9 | 53.6 ± 15.8 | 44.6 ± 15.8 |
BOLD brain activation signals in pre-defined ROI in response to checkerboard visual stimuli (flashing at 2 Hz). ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only.
No measurements were reported for this outcome.
Continuous ASL sequence fMRI imaging modality assessing brain activation signals across the whole brain and in defined ROI to assess effects of evoked pain along with changes in regional cerebral blood flow (rCBF). ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG.
No measurements were reported for this outcome.
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
No measurements were reported for this outcome.
BDI is a 21 item participant rated inventory evaluating depression symptoms, cognition, and physical symptoms of fatigue, weight loss, lack of interest in sex. Individual items are scored on a 4 point scale (0 to 3), with 0=none/absent and 3=most severe. Total score: 0 to 63; higher score indicate more depression.
No measurements were reported for this outcome.
Self-report scale completed by the participant. Separate scales measure state (20 items) and trait (20 items) anxiety. The participant report how they feel "right now at this moment" for state anxiety and how they "generally" feel for trait anxiety. The "state" items are scored as: 1 (not at all), 2 (somewhat true), 3 (moderately true), 4 (very much so). The "trait" items are scored as: 1 (almost never), 2 (sometimes), 3 (often), 4 (almost always). Scores range from 20-80 for each scale. Higher scores indicate more impaired participants.
No measurements were reported for this outcome.
The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all questions (range: 0 to 52); Subscale scores: Rumination (sum of scores for 4 items; range: 0 to 16); Magnification (sum of scores for 3 items; range: 0 to 12); and Helplessness (sum of scores for 6 items; range: 0 to 24); higher scores indicate greater extent of pain catastrophizing.
No measurements were reported for this outcome.
NPSI: participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicate a greater intensity of pain.
No measurements were reported for this outcome.
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning using 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). The daily pain scores for an average of the last 7 days and an average of last 3 days were calculated.
| units on a scale | Pregabalin | Tramadol | Placebo |
|---|---|---|---|
| Last 7 days | 5.57 ± 0.371 | 5.28 ± 0.370 | 6.40 ± 0.370 |
| Last 3 days | 5.46 ± 0.466 | 5.10 ± 0.454 | 6.33 ± 0.454 |
Participants answered: "Please rate your pain from 0-10 that best describes the intensity of pain right now". PPIS assessed on 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).
| units on a scale | Pregabalin | Tramadol | Placebo |
|---|---|---|---|
| Present Pain Intensity Score (PPIS) | 5.54 ± 0.552 | 4.13 ± 0.551 | 5.83 ± 0.551 |
DN4 questionnaire provides a simple diagnosis of Neuropathic pain (NeP) by asking for yes/no answers to 4 questions (10 sub questions in total). Each question was scored on a scale of 0 (No) and 1 (Yes). Total score was calculated as sum of the 10 individual questions. Total score range 0-10, higher score indicated more neuropathic pain.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 0/17 (0%) | 14/17 (82.4%) |
| Tramadol | — | 0/17 (0%) | 14/17 (82.4%) |
| Placebo | — | 0/18 (0%) | 11/18 (61.1%) |
| Event | Pregabalin | Tramadol | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/17 | 8/17 | 1/18 |
| DizzinessNervous system disorders | 7/17 | 8/17 | 2/18 |
| FatigueGeneral disorders | 3/17 | 6/17 | 1/18 |
| PruritusSkin and subcutaneous tissue disorders | 0/17 | 5/17 | 0/18 |
| ConstipationGastrointestinal disorders | 0/17 | 4/17 | 0/18 |
| VomitingGastrointestinal disorders | 0/17 | 4/17 | 0/18 |
| SomnolenceNervous system disorders | 2/17 | 4/17 | 1/18 |
| Dry mouthGastrointestinal disorders | 3/17 | 0/17 | 1/18 |
| NasopharyngitisInfections and infestations | 3/17 | 0/17 | 1/18 |
| Decreased appetiteMetabolism and nutrition disorders | 0/17 | 3/17 | 0/18 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 44.7 ± 9.7 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 12 |
| Male | 6 |
The record gives a start of Sep 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pregabalin · Tramadol
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →